| Source | Match | ReputationScore* | 
|---|---|---|
                RIO
                
                   Collection of samples and data across the following diseases: Malignant tumour of breast Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
                   
                
                 
             | 
            
                
                     | 
        
*ReputationScore indicates how established a given datasource is. Find out more.